Enliven Therapeutics, Inc. (ELVN:NASDAQ) closed at $41.52 on October 23, 2026, down 0.98% on the day. The stock trades 33.4% below its 52-week high of $62.32 and 180.8% above its 52-week low of $14.79. Over the past year, it gained 101.5%. Enliven Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, ELVN closed higher on 127 days (50%). Its best day was January 8, 2026 (+50.29%) and its worst was November 3, 2025 (-14.60%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 3 times.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially best-in-class or first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases.
Find more stocks like ELVN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.